The WuXi PharmaTech-backed molecular diagnostics technology developer has raised $27m that will go to commercialising its IDgenetix product.
AltheaDx, a US-based pharmacogenetics technology developer backed by pharmaceutical research company WuXi PharmaTech, received $27m in series D funding from undisclosed investors yesterday.
Founded in 2008, AltheaDx is working on a molecular diagnostics platform called IDgenetix that will help care providers choose the right drugs and dosages for patients based on their genetic profile.
The funding will be used to grow the company’s sales team and strengthen its marketing capabilities as it looks to secure partners for global expansion.
AltheaDx…
